Advancements of CAR-T Cell Therapies Importance Grows While Cancer Cases Increasing

PALM BEACH, Fla., April 14, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - CAR-T therapy is a sort of treatment in which a patient's T cells which is a type of immune system cell, are genetically modified to attack cancer cells in the lab. T cells are extracted from the blood of a patient. The gene for a specific receptor that binds to a specific protein on the patient's cancer cells is then transferred to T cells in the lab.  A chimeric antigen receptor is a unique type of receptor (CAR). CAR-T units are generated in large numbers in the lab and then infused into the patient. CAR-T therapy is used to treat specific types of blood malignancies, and it is also being researched for other cancers. CAR T therapy is also known as Chimeric antigen receptor T-cell therapy. T cells are used in CAR T therapy since they are generally responsible for destroying malignant cells and virus-infected cells. Cancer cells are known to hide from the immune system, but scientists have been able to improve T cells' ability to locate and kill cancer cells using CAR T therapy.  A report from Polaris Market Research projected that the global CAR-T cell therapy market was valued at USD 1,965.8 million in 2021, expected to grow at a CAGR of 31.16 % during the forecast period (2029).   The report said: "CAR T therapy market is expected to grow due to the growing prevalence of cancer cases across the globe. This treatment has captured the attention of researchers and the public because of the remarkable responses they have produced in patients. The Food and Drug Administration (FDA) approved two CAR T treatments in 2017, one for children with acute lymphoblastic leukaemia (ALL) and the other for adults with advanced lymphomas."   Active biotech and pharma companies in the markets this week include Oncolytics Biotech^® Inc. (NASDAQ: ONCY) (TSX: ONC), Sierra Oncology, Inc (NASDAQ: SRRA), Antares Pharma, Inc. (NASDAQ: ATRS), Clovis Oncology, Inc. (NASDAQ: CLVS), Turning Point Therapeutics, Inc. (NASDAQ: TPTX).